How will legal challenges fare against CMS rule on gender-affirming care?

August 14, 2026 - 05:04

A federal rule finalized this week by the Centers for Medicare and Medicaid Services could be harder to overturn than earlier Trump administration efforts to restrict gender-affirming treatment for minors. Legal experts say the agency's careful wording and reliance on statutory authority may shield it from the quick injunctions that doomed past policies.

The rule, which ties federal funding for hospitals and clinics to compliance with new restrictions on puberty blockers and hormone therapy for patients under 19, stops short of an outright ban. Instead, it requires providers to document "severe, life-threatening" circumstances before proceeding with treatment. That distinction matters in court, where judges have repeatedly struck down blanket prohibitions as arbitrary and capricious.

Previous attempts, including a 2025 executive order and a Department of Justice memo, were blocked within weeks by district courts citing a lack of congressional input and insufficient medical evidence. The CMS rule, however, was drafted after a formal comment period and cites specific studies on bone density and fertility risks. That procedural record gives it a stronger footing under the Administrative Procedure Act.

Still, challengers are already preparing lawsuits. The ACLU and Lambda Legal argue the rule violates equal protection by singling out transgender youth, and they point to conflicting findings from major pediatric associations. The first test will likely come in the Ninth Circuit, where judges have been skeptical of similar state laws. But even if a judge issues a temporary block, the rule's technical structure means a full repeal would require a lengthy trial, not just a quick ruling. For now, clinics in several states are pausing services to assess their legal exposure, while families face renewed uncertainty about access to care.